Vertex Pharmaceuticals Incorporated (NASDAQ ... and is pioneering treatments for T1D, including VX-880, a stem cell-derived therapy aimed at restoring insulin production. Clinical trials have ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

The current data for VX-880, as you know, which is in pivotal development ... the device was invented by our team was at Semma, now Vertex that are still all there as the device has novel ...

Vertex Pharmaceuticals Incorporated ... treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

As of 3:20:19 PM EDT. Market Open. Loading Chart for VRTX ...

As of March 10 at 12:33:44 p.m. EDT. Market Open.

As of March 10 at 1:10:07 p.m. EDT. Market Open.

As of 10 March at 3:59:30 pm GMT-4. Market open.